Dr. Giralt on Transplant Eligibility Criteria in Multiple Myeloma

Video

In Partnership With:

Sergio A. Giralt, MD, professor of medicine at Weill Cornell Medical College, and chief, Adult Bone Marrow Transplant Service, Melvin Berlin Family Chair in Multiple Myeloma, at Memorial Sloan Kettering Cancer Center, discusses transplant eligibility criteria in multiple myeloma.

Sergio A. Giralt, MD, professor of medicine at Weill Cornell Medical College, and chief, Adult Bone Marrow Transplant Service, Melvin Berlin Family Chair in Multiple Myeloma, at Memorial Sloan Kettering Cancer Center, discusses transplant eligibility criteria in multiple myeloma.

A patient’s performance status and comorbidities should be evaluated to determine whether they are a candidate for transplant, says Giralt. If eligible, patients over the age of 75 may also undergo a geriatric assessment to determine what type of transplant they are best suited to receive. Age is one factor that should not impact the decision, adds Giralt.

There is a belief that patients in renal failure on dialysis should not undergo transplant. However, studies have demonstrated that patients on dialysis can receive high-dose melphalan safely, enabling them to undergo transplant. Furthermore, some patients are able to subsequently recover kidney function and come off dialysis, concludes Giralt.

Related Videos
Jeremy M. Pantin, MD, clinical director, Adult Transplant and Cellular Therapy Program, TriStar Centennial Medical Center, bone marrow transplant physician, Sarah Cannon Research Institute
Maria Hafez, MD, assistant professor, breast and sarcoma medical oncologist, director, Clinical Breast Cancer Research, Sidney Kimmel Medical College, Thomas Jefferson University
Zeynep Eroglu, MD
Sundar Jagannath, MBBS, director, Center of Excellence for Multiple Myeloma, professor of medicine (hematology and medical oncology), The Tisch Cancer Institute, Mount Sinai
Akriti Jain, MD
Raj Singh, MD
Gottfried Konecny, MD
Karim Chamie, MD, associate professor, urology, the University of California, Los Angeles
Mike Lattanzi, MD, medical oncologist, Texas Oncology
Ramez N. Eskander, MD